Navigation Links
Stereotaxis Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/3/2008

p>Total revenue 10,254,863 14,005,580 39,298,809 27,191,706

Cost of revenue

System 2,954,061 5,011,858 10,978,108 10,448,772

Disposables,

service and

accessories 764,897 790,953 2,497,459 2,443,977

Inventory

impairment - - 1,870,653 -

Total cost of

revenue 3,718,958 5,802,811 15,346,220 12,892,749

Gross margin 6,535,905 8,202,769 23,952,589 14,298,957

Operating expenses:

Research and

development 5,996,138 4,547,773 25,471,809 21,794,177

General and

administration 4,589,694 4,071,212 18,701,726 16,642,359

Sales and marketing 8,287,708 6,086,065 29,021,117 22,533,882

Total operating

expenses 18,873,540 14,705,050 73,194,652 60,970,418

Operating loss (12,337,635) (6,502,281) (49,242,063) (46,671,461)

Interest income 258,859 488,344 1,471,503 2,126,987

Interest expense (134,455) (146,425) (350,954) (1,175,296)

Net loss $(12,213,231) $(6,160,362) $(48,121,514) $(45,719,770)

Net loss per common

share:

Basic and diluted $(0.34) $(0.18) $(1.34) $(1.39)

Weighted average

shares used in

computing net loss

per common share:

Basic and diluted 36,331,376 33,985,126 35,793,973 32,979,403

STEREOTAXIS, INC.

BALANCE SHEETS

December 31, December 31,

2007 2006

(Unaudited)

Assets

Current Assets:

Cash and cash equivalents
'/>"/>

SOURCE Stereotaxis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Stereotaxis Appoints David Burkhardt, M.D. as Chief Medical Officer
2. Stereotaxis Announces FDA Approval of Its Partnered Magnetic Irrigated Catheter
3. Stereotaxis Niobe System Used to Perform More Than 10,000 Procedures Worldwide
4. Genetic Engineering & Biotechnology News reports on advances in miRNA
5. Rosetta Genomics Reports Fourth-Quarter and Full-Year 2007 Financial Results
6. Warner Chilcott Reports Operating Results for the Quarter and Year ended December 31, 2007
7. Cepheid Reports Fourth Quarter and Full Year 2007 Results
8. Strategic Diagnostics Reports Fourth Quarter and Full-Year Financial Results
9. US Oncology Reports Fourth Quarter and Fiscal Year 2007 Results
10. Barr Reports GAAP Earnings of $1.18 Per Share for 2007 and $0.30 Per Share for the Fourth Quarter; Adjusted Earnings Were $3.16 Per Share for 2007 and $0.79 Per Share for the Fourth Quarter
11. Masimo Reports Fourth Quarter 2007 and Full Year 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... (PRWEB) January 14, 2014 Date: Friday, April ... Location: Warrington Country Club, 1360 Almshouse Road, Warrington, Pa. ... nonprofit organization solely dedicated to finding a cure for hepatitis ... worldwide, will host its annual Crystal Ball on Friday, April ...
(Date:1/14/2014)... (PRWEB) January 14, 2014 EquitiesIQ, a ... Inc. (OTCQB: ALQA). Alliqua is an emerging biomedical company ... the wound care market. , Free report download: ... with a seasoned management team and Board, which launched ...
(Date:1/14/2014)... 2014  RXi Pharmaceuticals Corporation (OTCQX: RXII), a biotechnology ... therapies addressing major unmet medical needs using RNA-targeted ... of Allowance from the United States Patent and ... (sd-rxRNA®), for the treatment of fibrosis. The patent ...
(Date:1/14/2014)... During the 1600’s through the 1800’s doctors ... Plague.” In this time period, doctors did not know that ... to the death of vulnerable patients. In the same way, ... may be unwittingly transmitting herpes viruses to their patients. The ...
Breaking Biology Technology:Hepatitis B Foundation to Host Annual Crystal Ball Gala 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 2RXi Pharmaceuticals Receives US Notice of Allowance for a Key Patent Relating to its Self-Delivering Technology with sd-rxRNAs targeting CTGF, including RXI-109, for the Treatment of Fibrotic Disorders 3Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... 21, 2009) A faster tool for cell programming and ... have won grand prizes of the 2009 Collegiate Inventors Competition, ... by the Abbott Fund, the non-profit foundation of the global ... Trademark Office (USPTO). Harris Wang, who invented a new ...
... Myriant Technologies LLC (Myriant), a privately-held, biotech developer ... of its Science Advisory Board and the appointment ... collectively will provide broad insight into all aspects ... biomass feedstocks into valuable chemicals. , (Logo: ...
... N.J. and WALTHAM, Mass., Oct. 21 BioWa, ... today that they have entered into an agreement ... POTELLIGENT(®) Technology platform for the development of antibody-dependent ... grants NKTT non-exclusive rights to research, develop, manufacture ...
Cached Biology Technology:Winners announced in 2009 Collegiate Inventors Competition 2Winners announced in 2009 Collegiate Inventors Competition 3Winners announced in 2009 Collegiate Inventors Competition 4Winners announced in 2009 Collegiate Inventors Competition 5Myriant Technologies LLC Announces Appointment of Science Advisory Board Members 2Myriant Technologies LLC Announces Appointment of Science Advisory Board Members 3BioWa and NKTT Announce Licensing of BioWa's POTELLIGENT(R) Technology For Use in Antibody Research and Development 2BioWa and NKTT Announce Licensing of BioWa's POTELLIGENT(R) Technology For Use in Antibody Research and Development 3
(Date:4/23/2014)... has transformed the energy landscape in the U.S., ... conflict among the energy industry, residents and agricultural ... add that degraded water quality is a potential ... article appears in the ACS journal Environmental ... and colleagues point out that a major criticism ...
(Date:4/23/2014)... the family of bacteria that causes whooping cough ... surprising findings about the bacteria,s origin and evolution. ... to control this respiratory disease, which kills 195,000 ... 343 strains of the Bordetella pertussis ... last 100 years illustrates how vaccination has shaped ...
(Date:4/23/2014)... quickly. It involves visual searching for clues to ... Similarly to humans, biological systems are sometimes under ... that need to be read quickly are usually ... easier it will be to read them quickly. ... Portugal) and Centre for Molecular and Structural Biomedicine ...
Breaking Biology News(10 mins):How to avoid water wars between 'fracking' industry and residents 2Impact of whooping cough vaccination revealed 2Cell division speed influences gene architecture 2
... is nicknamed "yellowcake" for its color and powdered consistency. ... , The yellow monster surfaced on the Navajo Nation ... continued for the next several decades. In its aftermath ... and worries about environmental contamination among people who live ...
... one day precisely release drugs and vaccines inside the ... study, by researchers at Ghent University and the Universit? ... Jan. 9, 2006, print issue of the American Chemical ... other microcapsules, which release their drug cargo only when ...
... study is being published in an advance online version of ... XPB helicase from an archaea, a single cell organism similar ... strands of the nucleic acid double helix, an action that ... well as other cell processes. , "XPB was initially ...
Cached Biology News:Study may help slay 'Yellow Monster' 2Study may help slay 'Yellow Monster' 3Enzyme crystal structure reveals 'unexpected' genome repair functions 2